Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00485082 · ClinicalTrials.gov registry record
Disclosing a Cystic Fibrosis Diagnosis to a Dating Partner
A clinical trial, sponsored by National Human Genome Research Institute (NHGRI).
- Completed
- Registry status
- 50
- Enrollment target
NCT00485082: Completed study, sponsored by National Human Genome Research Institute (NHGRI).
NCT00485082 is a clinical trial that has completed, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00485082 has completed, sponsored by National Human Genome Research Institute (NHGRI).
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
This study will examine the experience of disclosing a cystic fibrosis (CF) diagnosis to a dating partner. CF has implications for potential life partners (issues of fertility, decreased life span and an increasing need for medical management with age) that may make disclosure particularly sensitive. An understanding of the disclosure process may provide insight into ways health care practitioners can support their patients during this process. People between 21 and 35 years of age with CF who have been in at least one dating relationship may be eligible for this study. Participants are interviewed by telephone about their experiences living with cystic fibrosis and telling dating partners about their diagnosis. The interview includes questions about: * Past experiences disclosing their CF diagnosis to a dating partner * What information was disclosed versus what was not disclosed * Why certain information was disclosed or not disclosed * Positive and negative implications of the disclosure or non-disclosure The interview lasts about 60 minutes and is tape-recorded for later review and analysis.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2007-06-05 |
What the finished NCT00485082 record still lists
NCT00485082 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00485082 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00485082 about?
NCT00485082 is a clinical study titled "Disclosing a Cystic Fibrosis Diagnosis to a Dating Partner". This study will examine the experience of disclosing a cystic fibrosis (CF) diagnosis to a dating partner. CF has implications for potential life partners (issues of fertility, decreased life span and an increasing need for medical management with age) that may make disclosure particularly sensitive...
What is the current status of trial NCT00485082?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2007-06-05.
Who is sponsoring clinical trial NCT00485082?
This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI